Printer Friendly

Flu vaccine approved for upcoming season.

The influenza vaccine for the 2012-2013 season has been approved by the Food and Drug Administration, the agency has announced.

The three strains that are included are an A/California/7/2009 (H1N1)--like virus, which was included in the 2011-2012 influenza vaccine, and two new strains: an A/Victoria / 361/2011 (H3N2)--like virus, and a B/Wisconsin/1/2010--like virus.

"It is especially important to get vaccinated this year because two of the three virus strains used in this season's influenza vaccines differ from the strains included in last year's vaccines," Dr. Karen Midthun, director of the FDA's Center for Biologics Evaluation and Research, said in a statement.

Six manufacturers are licensed to produce and distribute influenza vaccine in the United States. The approved products are Afluria (CSL Limited); Fluarix (GlaxoSmithKline Biologicals); FluLaval (ID Biomedical Corp.); FluMist (MedImmune Vaccines); Fluvirin (Novartis Vaccines and Diagnostics Limited); and Fluzone, Fluzone High-Dose, and Fluzone Intradermal (Sanofi Pasteur).

Each year, the selection of strains to be included in the influenza vaccine is based on information about influenza virus circulating worldwide during the previous season and on recommendations from the FDA's Vaccines and Related Biological Products Advisory Committee.

The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recommends an annual influenza vaccine for everyone aged 6 months and older.
COPYRIGHT 2012 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Mechcatie, Elizabeth
Publication:OB GYN News
Date:Sep 1, 2012
Words:219
Previous Article:Thyroid disorder in pregnancy guide updated: from the journal of clinical endocrinology and metabolism.
Next Article:Modify risks for failed epidural conversion: at the annual meeting of the Society for obstetric anesthesia and perinatology.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters